Paper published in a journal (Scientific congresses and symposiums)
38MO Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial
Mirza, M.R.; Ghamande, S.; Hanker, L.C. et al.
2024In ESMO Open, 9, p. 103538
Peer Reviewed verified by ORBi
 

Files


Full Text
38MO-Progression-free-survival--PFS--in-primary-advanced-or-recurren_2024_ES Copy.pdf
Publisher postprint (139.87 kB) Creative Commons License - Attribution, Non-Commercial, No Derivative
Download

All documents in ORBi are protected by a user license.

Send to



Details



Disciplines :
Oncology
Author, co-author :
Mirza, M.R.
Ghamande, S.
Hanker, L.C.
Black, D.
Raaschou-Jensen, N.
Gilbert, L.
Oaknin, A.
Secord, A.A.
Savarese, A.
Holloway, R.W.
Kristeleit, R.
Buscema, J.
Boere, I.A.
Sharma, S.
Gennigens, Christine  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Ghatage, P.
Yablonski, K.
Stevens, S.
Trukhan, H.
Powell, M.A.
More authors (10 more) Less
Language :
English
Title :
38MO Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial
Publication date :
June 2024
Event name :
ESMO Gynaecological Cancers Congress 2024
Event date :
20-22 Jun 2024
Audience :
International
Journal title :
ESMO Open
eISSN :
2059-7029
Publisher :
Elsevier BV
Volume :
9
Pages :
103538
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 02 July 2024

Statistics


Number of views
5 (3 by ULiège)
Number of downloads
3 (0 by ULiège)

Bibliography


Similar publications



Contact ORBi